Advertisement

Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis

  • Jia Tong Song
    Affiliations
    Faculty of Medicine, University of British Columbia
    Search for articles by this author
  • Sameer Desai
    Affiliations
    School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
    Search for articles by this author
  • Alessandro N. Franciosi
    Affiliations
    Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada

    Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Search for articles by this author
  • Renee V.E. Dagenais
    Affiliations
    Department of Pharmacy, St. Paul's Hospital, Vancouver, BC, Canada

    Adult Cystic Fibrosis Program, St. Paul's Hospital, Vancouver, BC, Canada
    Search for articles by this author
  • Bradley S. Quon
    Correspondence
    Corresponding author at: #166 - 1081 Burrard Street. Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada.
    Affiliations
    Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada

    Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Search for articles by this author

      Highlights

      • Reducing treatment burden is a high priority for people living with CF.
      • Standard of care involves the use of multiple nebulized therapies which are time consuming.
      • Prescription refills for nebulized dornase alfa and hypertonic saline decreased in the first year post-ETI.
      • Several ongoing studies are evaluating the safety of withdrawing nebulized therapies post-ETI.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sawicki G.S.
        • Sellers D.E.
        • Robinson W.M.
        High treatment burden in adults with cystic fibrosis: challenges to disease self-management.
        J Cyst Fibros. 2009; 8 (Mar): 91-96
        • Heijerman H.G.M.
        • McKone E.F.
        • Downey D.G.
        • Van Braeckel E.
        • Rowe S.M.
        • Tullis E.
        • et al.
        Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
        Lancet. 2019; 394 (Nov 23): 1940-1948
        • Middleton P.G.
        • Mall M.A.
        • Dřevínek P.
        • et al.
        Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single phe508del allele.
        N Engl J Med. 2019; 381 (Nov 7): 1809-1819
        • Munce D.
        • Lim M.
        • Akong K.
        Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
        Pediatr Pulmonol. 2020; 55: 3381-3383
        • Quittner A.L.
        • Zhang J.
        • Marynchenko M.
        • Chopra P.A.
        • Signorovitch J.
        • Yushkina Y.
        • et al.
        Pulmonary medication adherence and health-care use in cystic fibrosis.
        Chest. 2014 Jan 30; 146: 142-151